New hope for End-Stage colon cancer patients in major drug trial
NCT ID NCT03829462
Summary
This study is for people with advanced colorectal cancer that has spread and has stopped responding to all standard treatments. It compares two approaches: taking the drug regorafenib alone versus taking regorafenib combined with another drug called irinotecan. The main goal is to see if the drug combination helps patients live longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (MCRC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CRLC Val d'Aurelle-Paul Lamarque
Montpellier, 34298, France
-
Centre Antoine Lacassagne
Nice, Alpes-Maritimes, 06189, France
-
Centre François Baclesse
Caen, Basse-Normandie, 14000, France
-
Centre Léon Bérard
Lyon, Rhône, 69008, France
-
Hôpital Européen Georges Pompidou
Paris, 75015, France
-
Hôpital Pontchaillou
Rennes, Ile Et Vilaine, 35000, France
-
Hôpital Robert Debré
Reims, Marne, 51100, France
-
Hôpital Saint-Jean
Perpignan, Pyrénées-orientales, 66000, France
-
Hôpital privé Jean Mermoz
Lyon, Rhône, 69008, France
-
Institut Godinot
Reims, Marne, 51100, France
-
Institut Gustave Roussy
Villejuif, Val De Marne, 94800, France
Conditions
Explore the condition pages connected to this study.